<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02634151</url>
  </required_header>
  <id_info>
    <org_study_id>GEM-301</org_study_id>
    <nct_id>NCT02634151</nct_id>
  </id_info>
  <brief_title>A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins</brief_title>
  <acronym>ROYAL-1</acronym>
  <official_title>A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroBo Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroBo Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the efficacy, safety, and tolerability of multiple
      doses of gemcabene 600 mg QD compared to placebo in patients with hypercholesterolemia not
      adequately controlled on high-intensity or moderate-intensity stable statin therapy. Patients
      with HeFH, ASCVD, or otherwise uncontrolled, may be included with baseline LDL-C value ≥ 100
      mg/dL. Subjects were randomized 1:1 to gemcabene 600 mg once daily (QD) or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in LDL-C by Statin Intensity Stratum</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The intensity of statin therapy was determined based on the statin dose.Participants were categorized as high intensity &amp; moderate intensity based on their statin doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12 and average of weeks 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in LDL-C</measure>
    <time_frame>Baseline, average of weeks 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C</measure>
    <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Non-HDL-C</measure>
    <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in TC</measure>
    <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TC</measure>
    <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in TG</measure>
    <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TG</measure>
    <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in VLDL-C</measure>
    <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in VLDL-C</measure>
    <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in HDL-C</measure>
    <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HDL-C</measure>
    <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving LDL-C Reduction of ≥10%</measure>
    <time_frame>Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving LDL-C Reduction of ≥15%</measure>
    <time_frame>Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving LDL-C Reduction of ≥20%</measure>
    <time_frame>Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving an LDL-C Value &lt;100 mg/dL (2.59 mmol/L)</measure>
    <time_frame>Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein B</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein A-I</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein A-I</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein A-II</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein A-II</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein C-II</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein C-II</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein C-III</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein C-III</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein E</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein E</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein(a)</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipoprotein(a)</measure>
    <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-sensitivity C-reactive Protein</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High-sensitivity C-reactive Protein</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fibrinogen</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fibrinogen</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Amyloid A</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Amyloid A</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Adiponectin</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adiponectin</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Framingham Risk Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Framingham Risk Score was an estimate of a participant's 10-year risk of developing cardiovascular disease which was computed using sex-specific algorithms based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) : which was derived of participant's age, systolic blood pressure , smoking status, TC, HDL-C, treatment for hypertension, and diabetes status. Reported score is a percentage. Change from baseline calculated as mean at week 12 minus mean at baseline. Negative scores indicate less risk of developing cardiovascular disease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Hypercholesteremia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on stable statin therapy received 600 milligrams (mg) of Gemcabene orally, once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene</intervention_name>
    <description>Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.</description>
    <arm_group_label>Gemcabene 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three placebo tablets administered orally once daily for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Provision of written and signed informed consent (by subject or legal guardian) prior
             to any study-specific procedures;

          2. Male or female (neither pregnant or lactating) ≥ 18 years of age at the time of
             consent;

          3. Currently on a stable, low-fat, low-cholesterol diet in combination with allowed
             statin doses as described in Table 1, with or without ezetimibe 10 mg QD for at least
             12 weeks prior to the Screening Visit;

          4. Fasting LDL-C value ≥ 100 mg/dL (2.59 mmol/L) at the Screening Visit;

          5. Physical examination, including vital signs, that is within normal limits or
             clinically acceptable to the Investigator;

          6. Weight ≥ 50 kg; with a body mass index (BMI) ≤ 45 kg/m2

          7. Subjects with Type 2 diabetes who take anti-hyperglycemic agents must be on a stable
             regimen for at least 3 months, with no planned changes in medications for the study
             duration.

        Exclusion Criteria

          1. Abnormal liver function test at the Pre-Screening or Screening Visit (AST or ALT) &gt; 2x
             ULN (upper limit of normal), total bilirubin &gt; 1.5x ULN, or alkaline phosphate &gt; 2x
             ULN based on appropriate age and gender normal values. Subjects with bilirubin &gt; 1.5x
             ULN and a history of Gilbert's syndrome may be included; reflexive direct bilirubin
             testing will be used to confirm Gilbert's syndrome;

          2. Moderate (Grade B) or severe (Grade C) chronic hepatic impairment according to the
             Child-Pugh classification;

          3. Active liver disease (e.g. cirrhosis, alcoholic liver disease, hepatitis B, hepatitis
             C, autoimmune hepatitis, liver failure, liver cancer), history of liver transplant,
             known diagnosis of HIV or AIDS;

          4. Triglyceride value ≥ 500 mg/dL at the Pre-Screening Visit or the Screening Visit;

          5. Moderate to severe renal insufficiency define as an estimated GFR &lt; 60mL/min/1.73m
             (calculated using the Chronic Kidney Disease Epidemiology Collaboration equation) at
             the Pre-Screening Visit or Screening Visit;

          6. Abnormal urinalysis (proteinuria greater than trace or any male or non-menstruating
             female with greater than trace hematuria) confirmed by reflexive urine
             protein:creatinine ration testing;

          7. Uncontrolled thyroid disease; hyperthyroidism or hypothyroidism as defined by thyroid
             stimulating hormone (TSH) below the lower limit of normal or &gt; 1.5x ULN, respectively,
             based on results from the Pre-Screening Visit or the Screening Visit. If controlled,
             treatment should be stable for at least 3 months prior to Screening;

          8. Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (hemoglobin A1c
             value &gt; 8.5% based on results from the Pre-Screening or Screening Visit, or taking a
             thiazolidinedione (i.e. pioglitazone or rosiglitazone);

          9. New York Heart Association Class III or IV heart failure;

         10. Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty,
             coronary artery bypass graft, or other major cardiovascular events resulting in
             hospitalization within 3 months of the Screening Visit. Subjects with adequately
             treated stable angina, per Investigator assessment, may be included;

         11. Uncontrolled cardiac arrhythmia or prolonged QT on the Screening Visit or Day 1 prior
             to dosing ECG (QTcF &gt; 450 msec for men and &gt; 470 msec for women) or known family
             history of prolonged QT or unexplained sudden cardiac death;

         12. Uncontrolled hypertension, defined as sitting systolic blood pressure &gt; 180 mmHg or
             diastolic blood pressure &gt; 110 mmHg, and confirmed by repeat measurement;

         13. Currently receiving cancer treatments or, in the Investigator's opinion, at risk of
             relapse for recent cancer;

         14. Inadequate wash-out of a PCSK9 inhibitor (8 weeks prior to the Screening Visit), a
             fibrate lipid-regulating agent (6 weeks prior to the Screening Visit), niacins (4
             weeks prior to the Screening Visit), or other lipid-regulating therapies such as bile
             acid sequestrants (4 weeks prior to the Screening Visit);

         15. Hypersensitivity to or a history of significant adverse reactions to any fibrate
             lipid-regulating agent;

         16. Use of any excluded medications or supplements (e.g. potent cytochrome P450 [CYP] 3A4
             inhibitors as described in Appendix D;

         17. History of drug or alcohol abuse within the past year or inability to comply with
             protocol requirements, including subjects restrictions (see Section 5.6.3);

         18. Previously treated with gemcabene (CI-1027), participation in another clinical study
             of an investigational agent or device concurrently or within 1 month prior the
             Screening Visit, or use of an investigational agent within 1 month or 5 half-lives (if
             known), whichever is longer, prior to the Screening Visit;

         19. Any other finding which, in the opinion of the Investigator, would compromise the
             subject's safety or participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Central Research Associates, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Medical Associates of Los Angeles</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Clinical Research Collaborative- Cardiology</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excel Medical Clinical Trials</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research, Inc.</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Varkey Medical</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Premier Healthcare Research, LLC</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-MARC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Hudson Medical Research</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentral Clinical Research Services</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Green and Seidner Family Practice Associates</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Grup</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sugar Lakes Family Practice</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 11, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <results_first_submitted>June 3, 2020</results_first_submitted>
  <results_first_submitted_qc>June 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2020</results_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDL‐C</keyword>
  <keyword>Lipid Regulator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02634151/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02634151/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants who had heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) and were on a statin therapy were enrolled in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gemcabene 600 mg</title>
          <description>Participants on stable statin therapy received 600 milligrams (mg) of Gemcabene orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS): All randomized participants who received at least 1 dose of the study drug and had at least 1 post-baseline efficacy assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Gemcabene 600 mg</title>
          <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="9.30"/>
                    <measurement group_id="B2" value="59.0" spread="9.67"/>
                    <measurement group_id="B3" value="60.8" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-density lipoprotein cholesterol (LDL-C)</title>
          <units>Milligram per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.83" spread="24.107"/>
                    <measurement group_id="B2" value="126.49" spread="28.101"/>
                    <measurement group_id="B3" value="130.20" spread="26.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-high-density lipoprotein cholesterol (non-HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.17" spread="29.664"/>
                    <measurement group_id="B2" value="154.31" spread="32.796"/>
                    <measurement group_id="B3" value="158.28" spread="31.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol (TC)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="216.68" spread="28.643"/>
                    <measurement group_id="B2" value="206.16" spread="31.848"/>
                    <measurement group_id="B3" value="211.47" spread="30.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides (TG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141.57" spread="60.696"/>
                    <measurement group_id="B2" value="138.80" spread="65.088"/>
                    <measurement group_id="B3" value="140.20" spread="62.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-density lipoprotein cholesterol (HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.51" spread="14.594"/>
                    <measurement group_id="B2" value="51.86" spread="13.097"/>
                    <measurement group_id="B3" value="53.20" spread="13.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very low-density lipoprotein cholesterol (VLDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.34" spread="12.114"/>
                    <measurement group_id="B2" value="27.82" spread="13.048"/>
                    <measurement group_id="B3" value="28.08" spread="12.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C by Statin intensity stratum</title>
          <description>The intensity of statin therapy was determined based on the statin dose.Participants were categorized as high intensity &amp; moderate intensity based on their statin doses.</description>
          <population>FAS Population.Here, number analyzed signifies those participants who were evaluable in each category.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Moderate-intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128.91" spread="18.742"/>
                    <measurement group_id="B2" value="124.54" spread="28.104"/>
                    <measurement group_id="B3" value="126.76" spread="23.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139.34" spread="28.356"/>
                    <measurement group_id="B2" value="128.60" spread="28.521"/>
                    <measurement group_id="B3" value="133.97" spread="28.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B (ApoB)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.0" spread="19.61"/>
                    <measurement group_id="B2" value="100.1" spread="22.22"/>
                    <measurement group_id="B3" value="104.1" spread="21.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein A-I (ApoA-I)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155.3" spread="22.14"/>
                    <measurement group_id="B2" value="148.8" spread="25.45"/>
                    <measurement group_id="B3" value="152.1" spread="23.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein A-II (ApoA-II)</title>
          <population>FAS Population. Here, number analyzed signifies participants with available data.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.9" spread="5.38"/>
                    <measurement group_id="B2" value="36.0" spread="5.86"/>
                    <measurement group_id="B3" value="36.5" spread="5.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein C-II (ApoC-II)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="2.45"/>
                    <measurement group_id="B2" value="5.5" spread="2.65"/>
                    <measurement group_id="B3" value="5.5" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein C-III (ApoC-III)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" spread="3.40"/>
                    <measurement group_id="B2" value="10.7" spread="3.69"/>
                    <measurement group_id="B3" value="10.8" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein E (ApoE)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="0.97"/>
                    <measurement group_id="B2" value="4.2" spread="1.08"/>
                    <measurement group_id="B3" value="4.3" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-sensitivity C-reactive protein (hsCRP)</title>
          <units>milligram per Liter (mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.93" spread="2.792"/>
                    <measurement group_id="B2" value="3.91" spread="4.779"/>
                    <measurement group_id="B3" value="3.42" spread="3.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fibrinogen</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="453.5" spread="113.26"/>
                    <measurement group_id="B2" value="460.7" spread="92.22"/>
                    <measurement group_id="B3" value="457.1" spread="102.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipoprotein(a)</title>
          <units>Nanomole per liter (nmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.4" spread="123.23"/>
                    <measurement group_id="B2" value="113.8" spread="102.59"/>
                    <measurement group_id="B3" value="109.1" spread="113.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adiponectin</title>
          <units>Microgram per milliliter (μg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" spread="4.90"/>
                    <measurement group_id="B2" value="6.6" spread="3.98"/>
                    <measurement group_id="B3" value="6.7" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum amyloid A</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="3.20"/>
                    <measurement group_id="B2" value="8.6" spread="11.01"/>
                    <measurement group_id="B3" value="7.2" spread="816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Framingham Risk Score</title>
          <description>Framingham Risk Score was an estimate of a participant's 10-year risk of developing cardiovascular disease which was computed using sex-specific algorithms based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) which was derived of participant’s age, systolic blood pressure, smoking status, TC, HDL-C, treatment for hypertension, and diabetes status.Reported score is a percentage.</description>
          <units>Percentage (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.109" spread="13.8630"/>
                    <measurement group_id="B2" value="15.381" spread="11.4957"/>
                    <measurement group_id="B3" value="16.758" spread="12.7583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in LDL-C at Week 12</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS Population. Missing values were imputed by Last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at Week 12</title>
          <population>FAS Population. Missing values were imputed by Last observation carried forward (LOCF).</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.03" spread="3.234"/>
                    <measurement group_id="O2" value="-4.98" spread="3.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0057</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.81</ci_lower_limit>
            <ci_upper_limit>-3.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in LDL-C by Statin Intensity Stratum</title>
        <description>The intensity of statin therapy was determined based on the statin dose.Participants were categorized as high intensity &amp; moderate intensity based on their statin doses.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF. Here, Number analyzed signifies those participants who were evaluable in each category.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C by Statin Intensity Stratum</title>
          <description>The intensity of statin therapy was determined based on the statin dose.Participants were categorized as high intensity &amp; moderate intensity based on their statin doses.</description>
          <population>FAS Population. Missing values were imputed by LOCF. Here, Number analyzed signifies those participants who were evaluable in each category.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.58" spread="4.739"/>
                    <measurement group_id="O2" value="-8.94" spread="4.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.05" spread="4.732"/>
                    <measurement group_id="O2" value="-1.25" spread="4.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>High-Intensity.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0648</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group and baseline diabetes status are included as factors, and the outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.35</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate Intensity.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0398</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group and baseline diabetes status are included as factors, and the outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.77</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C</title>
        <time_frame>Baseline, Weeks 2, 4, 8, 12 and average of weeks 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.69" spread="3.731"/>
                    <measurement group_id="O2" value="-15.60" spread="3.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.72" spread="3.958"/>
                    <measurement group_id="O2" value="-11.32" spread="4.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.97" spread="4.172"/>
                    <measurement group_id="O2" value="-18.86" spread="4.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.40" spread="4.059"/>
                    <measurement group_id="O2" value="-7.77" spread="4.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average of week 8 and 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.19" spread="3.717"/>
                    <measurement group_id="O2" value="-13.32" spread="3.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0275</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.04</ci_lower_limit>
            <ci_upper_limit>-1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0524</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-9.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.90</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.8602</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.12</ci_lower_limit>
            <ci_upper_limit>10.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0115</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-12.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.37</ci_lower_limit>
            <ci_upper_limit>-2.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Average of week 8 and 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.1945</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.79</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in LDL-C</title>
        <time_frame>Baseline, average of weeks 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.15" spread="2.921"/>
                    <measurement group_id="O2" value="-9.27" spread="3.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0991</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.89</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C</title>
        <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-HDL-C</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.60" spread="2.397"/>
                    <measurement group_id="O2" value="-10.01" spread="2.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.27" spread="2.664"/>
                    <measurement group_id="O2" value="-3.71" spread="2.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.35" spread="2.831"/>
                    <measurement group_id="O2" value="-11.41" spread="2.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.48" spread="2.860"/>
                    <measurement group_id="O2" value="-3.79" spread="2.936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0101</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.32</ci_lower_limit>
            <ci_upper_limit>-1.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0037</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-9.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.94</ci_lower_limit>
            <ci_upper_limit>-3.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.7839</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.72</ci_lower_limit>
            <ci_upper_limit>5.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0025</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.53</ci_lower_limit>
            <ci_upper_limit>-3.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Non-HDL-C</title>
        <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Non-HDL-C</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.21" spread="4.088"/>
                    <measurement group_id="O2" value="-16.55" spread="4.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.88" spread="4.318"/>
                    <measurement group_id="O2" value="-6.33" spread="4.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.45" spread="4.551"/>
                    <measurement group_id="O2" value="-18.86" spread="4.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.21" spread="4.451"/>
                    <measurement group_id="O2" value="-6.62" spread="4.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0117</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-12.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.45</ci_lower_limit>
            <ci_upper_limit>-2.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0036</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-15.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.88</ci_lower_limit>
            <ci_upper_limit>-5.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.9147</p_value>
            <p_value_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.48</ci_lower_limit>
            <ci_upper_limit>10.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0026</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-16.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.24</ci_lower_limit>
            <ci_upper_limit>-5.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in TC</title>
        <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in TC</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.10" spread="1.923"/>
                    <measurement group_id="O2" value="-7.97" spread="1.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.35" spread="2.136"/>
                    <measurement group_id="O2" value="-2.62" spread="2.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.77" spread="2.236"/>
                    <measurement group_id="O2" value="-8.88" spread="2.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.79" spread="2.161"/>
                    <measurement group_id="O2" value="-2.90" spread="2.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0101</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.77</ci_lower_limit>
            <ci_upper_limit>-1.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0036</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.89</ci_lower_limit>
            <ci_upper_limit>-2.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.9653</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.27</ci_lower_limit>
            <ci_upper_limit>5.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0101</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.10</ci_lower_limit>
            <ci_upper_limit>-1.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TC</title>
        <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TC</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.47" spread="4.331"/>
                    <measurement group_id="O2" value="-17.73" spread="4.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.37" spread="4.514"/>
                    <measurement group_id="O2" value="-6.08" spread="4.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.10" spread="4.741"/>
                    <measurement group_id="O2" value="-19.68" spread="4.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.90" spread="4.500"/>
                    <measurement group_id="O2" value="-6.92" spread="4.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0173</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-12.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.19</ci_lower_limit>
            <ci_upper_limit>-2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0038</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-16.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.17</ci_lower_limit>
            <ci_upper_limit>-5.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.7846</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.85</ci_lower_limit>
            <ci_upper_limit>13.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0121</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-13.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.83</ci_lower_limit>
            <ci_upper_limit>-3.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in TG</title>
        <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in TG</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.58" spread="4.251"/>
                    <measurement group_id="O2" value="2.64" spread="4.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.28" spread="4.706"/>
                    <measurement group_id="O2" value="17.31" spread="4.807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.94" spread="3.743"/>
                    <measurement group_id="O2" value="1.76" spread="3.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.22" spread="5.245"/>
                    <measurement group_id="O2" value="7.42" spread="5.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0108</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-13.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.32</ci_lower_limit>
            <ci_upper_limit>-3.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-23.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.78</ci_lower_limit>
            <ci_upper_limit>-12.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.1376</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.60</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0144</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-15.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.10</ci_lower_limit>
            <ci_upper_limit>-3.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TG</title>
        <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TG</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.88" spread="6.322"/>
                    <measurement group_id="O2" value="0.65" spread="6.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.08" spread="7.132"/>
                    <measurement group_id="O2" value="27.56" spread="7.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.17" spread="5.238"/>
                    <measurement group_id="O2" value="0.16" spread="5.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.94" spread="10.194"/>
                    <measurement group_id="O2" value="13.64" spread="10.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0113</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-19.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.55</ci_lower_limit>
            <ci_upper_limit>-4.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-33.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.58</ci_lower_limit>
            <ci_upper_limit>-16.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.1873</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-8.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.77</ci_lower_limit>
            <ci_upper_limit>4.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0172</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-29.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.80</ci_lower_limit>
            <ci_upper_limit>-5.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in VLDL-C</title>
        <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in VLDL-C</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.55" spread="4.104"/>
                    <measurement group_id="O2" value="0.97" spread="4.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.63" spread="4.632"/>
                    <measurement group_id="O2" value="16.38" spread="4.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.69" spread="3.687"/>
                    <measurement group_id="O2" value="1.74" spread="3.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.69" spread="4.155"/>
                    <measurement group_id="O2" value="3.94" spread="4.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0210</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.27</ci_lower_limit>
            <ci_upper_limit>-1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-23.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.02</ci_lower_limit>
            <ci_upper_limit>-12.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.1483</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.19</ci_lower_limit>
            <ci_upper_limit>2.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0214</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.50</ci_lower_limit>
            <ci_upper_limit>-1.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in VLDL-C</title>
        <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in VLDL-C</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.64" spread="1.124"/>
                    <measurement group_id="O2" value="-0.69" spread="1.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="1.371"/>
                    <measurement group_id="O2" value="5.02" spread="1.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="1.034"/>
                    <measurement group_id="O2" value="0.01" spread="1.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="1.279"/>
                    <measurement group_id="O2" value="1.11" spread="1.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0308</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.62</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.56</ci_lower_limit>
            <ci_upper_limit>-3.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.2056</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.03</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0103</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.04</ci_lower_limit>
            <ci_upper_limit>-0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in HDL-C</title>
        <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in HDL-C</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.73" spread="1.771"/>
                    <measurement group_id="O2" value="-0.60" spread="1.821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="1.888"/>
                    <measurement group_id="O2" value="2.01" spread="1.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="2.112"/>
                    <measurement group_id="O2" value="0.37" spread="2.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="2.129"/>
                    <measurement group_id="O2" value="1.08" spread="2.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3193</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.36</ci_lower_limit>
            <ci_upper_limit>2.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.2932</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.91</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.4383</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.06</ci_lower_limit>
            <ci_upper_limit>7.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.2814</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.31</ci_lower_limit>
            <ci_upper_limit>7.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HDL-C</title>
        <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HDL-C</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="0.964"/>
                    <measurement group_id="O2" value="-0.41" spread="0.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="1.004"/>
                    <measurement group_id="O2" value="0.65" spread="1.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="1.099"/>
                    <measurement group_id="O2" value="0.11" spread="1.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="1.182"/>
                    <measurement group_id="O2" value="0.62" spread="1.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.4278</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.23</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.3529</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.53</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.3522</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>3.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.2635</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>4.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving LDL-C Reduction of ≥10%</title>
        <time_frame>Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving LDL-C Reduction of ≥10%</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0464</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>4.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.5278</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0359</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>5.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving LDL-C Reduction of ≥15%</title>
        <time_frame>Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving LDL-C Reduction of ≥15%</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0268</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>5.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2755</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>3.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.05</ci_lower_limit>
            <ci_upper_limit>10.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving LDL-C Reduction of ≥20%</title>
        <time_frame>Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving LDL-C Reduction of ≥20%</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0079</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>7.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.4002</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>3.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0142</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>7.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving an LDL-C Value &lt;100 mg/dL (2.59 mmol/L)</title>
        <time_frame>Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving an LDL-C Value &lt;100 mg/dL (2.59 mmol/L)</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0115</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>10.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.7566</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0298</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>7.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="2.81"/>
                    <measurement group_id="O2" value="1.8" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="2.53"/>
                    <measurement group_id="O2" value="-5.5" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="2.79"/>
                    <measurement group_id="O2" value="1.0" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0029</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.2</ci_lower_limit>
            <ci_upper_limit>-3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.1666</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.4</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0010</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.2</ci_lower_limit>
            <ci_upper_limit>-4.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein B</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein B</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="2.74"/>
                    <measurement group_id="O2" value="0.1" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="2.64"/>
                    <measurement group_id="O2" value="-7.3" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.0" spread="2.86"/>
                    <measurement group_id="O2" value="-0.4" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0018</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.3</ci_lower_limit>
            <ci_upper_limit>-4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.2437</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.1</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.5</ci_lower_limit>
            <ci_upper_limit>-4.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein A-I</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein A-I</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.45"/>
                    <measurement group_id="O2" value="3.7" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="1.53"/>
                    <measurement group_id="O2" value="3.8" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.60"/>
                    <measurement group_id="O2" value="2.8" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.6832</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.6740</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.3379</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein A-I</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein A-I</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.14"/>
                    <measurement group_id="O2" value="4.4" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="2.36"/>
                    <measurement group_id="O2" value="4.8" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="2.50"/>
                    <measurement group_id="O2" value="3.3" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.7753</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.5472</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.2406</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein A-II</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed signifies those who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein A-II</title>
          <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed signifies those who were evaluable for this outcome measure.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.49"/>
                    <measurement group_id="O2" value="1.9" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.84"/>
                    <measurement group_id="O2" value="-1.4" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.80"/>
                    <measurement group_id="O2" value="-0.9" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.9028</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0199</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0369</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>8.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein A-II</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed signifies those who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein A-II</title>
          <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed signifies those who were evaluable for this outcome measure.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.54"/>
                    <measurement group_id="O2" value="0.4" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.69"/>
                    <measurement group_id="O2" value="-0.8" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.66"/>
                    <measurement group_id="O2" value="-0.7" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.9110</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0243</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0388</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein C-II</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein C-II</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="5.34"/>
                    <measurement group_id="O2" value="13.1" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="6.95"/>
                    <measurement group_id="O2" value="3.9" spread="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="7.07"/>
                    <measurement group_id="O2" value="7.2" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.2799</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>7.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>19.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0018</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>26.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.2</ci_lower_limit>
            <ci_upper_limit>43.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0197</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>20.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.3</ci_lower_limit>
            <ci_upper_limit>36.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein C-II</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein C-II</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.19"/>
                    <measurement group_id="O2" value="0.00" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.24"/>
                    <measurement group_id="O2" value="-0.3" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.27"/>
                    <measurement group_id="O2" value="0.00" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0179</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0095</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein C-III</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein C-III</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="3.61"/>
                    <measurement group_id="O2" value="12.6" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="3.56"/>
                    <measurement group_id="O2" value="1.8" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="4.32"/>
                    <measurement group_id="O2" value="9.7" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0057</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-12.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.8</ci_lower_limit>
            <ci_upper_limit>-3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.9665</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.3</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.2358</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.4</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein C-III</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein C-III</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.39"/>
                    <measurement group_id="O2" value="1.4" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.38"/>
                    <measurement group_id="O2" value="0.0" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.44"/>
                    <measurement group_id="O2" value="0.9" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0048</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.9064</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.2505</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein E</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein E</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="2.86"/>
                    <measurement group_id="O2" value="9.1" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="2.89"/>
                    <measurement group_id="O2" value="-0.1" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="3.16"/>
                    <measurement group_id="O2" value="7.5" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-15.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.6</ci_lower_limit>
            <ci_upper_limit>-9.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0406</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.0</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-15.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.8</ci_lower_limit>
            <ci_upper_limit>-7.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein E</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein E</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.11"/>
                    <measurement group_id="O2" value="0.3" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.12"/>
                    <measurement group_id="O2" value="-0.1" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.15"/>
                    <measurement group_id="O2" value="0.3" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0771</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein(a)</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein(a)</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="4.61"/>
                    <measurement group_id="O2" value="-5.1" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="3.94"/>
                    <measurement group_id="O2" value="-4.0" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="5.18"/>
                    <measurement group_id="O2" value="0.1" spread="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.1210</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>19.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0948</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>8.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>17.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.5113</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.2</ci_lower_limit>
            <ci_upper_limit>16.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipoprotein(a)</title>
        <time_frame>Baseline, Weeks 4, 8 and 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipoprotein(a)</title>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="3.97"/>
                    <measurement group_id="O2" value="-3.6" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="3.16"/>
                    <measurement group_id="O2" value="-2.6" spread="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="4.00"/>
                    <measurement group_id="O2" value="1.7" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.7276</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.8</ci_lower_limit>
            <ci_upper_limit>11.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.2218</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.9420</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.2</ci_lower_limit>
            <ci_upper_limit>9.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-sensitivity C-reactive Protein</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-sensitivity C-reactive Protein</title>
          <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.33" spread="64.525"/>
                    <measurement group_id="O2" value="24.76" spread="66.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.6786</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>32.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-122.98</ci_lower_limit>
            <ci_upper_limit>188.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High-sensitivity C-reactive Protein</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High-sensitivity C-reactive Protein</title>
          <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.495"/>
                    <measurement group_id="O2" value="0.44" spread="0.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.1648</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.03</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fibrinogen</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fibrinogen</title>
          <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" spread="47.59"/>
                    <measurement group_id="O2" value="20.3" spread="48.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.4701</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>41.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.1</ci_lower_limit>
            <ci_upper_limit>155.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fibrinogen</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fibrinogen</title>
          <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="13.69"/>
                    <measurement group_id="O2" value="41.4" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0517</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-32.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.1</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Amyloid A</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Amyloid A</title>
          <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" spread="69.71"/>
                    <measurement group_id="O2" value="44.1" spread="71.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.9111</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-177.8</ci_lower_limit>
            <ci_upper_limit>158.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Amyloid A</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Amyloid A</title>
          <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.87"/>
                    <measurement group_id="O2" value="2.6" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.3864</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Adiponectin</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Adiponectin</title>
          <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="4.10"/>
                    <measurement group_id="O2" value="5.4" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0145</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>12.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.5</ci_lower_limit>
            <ci_upper_limit>22.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adiponectin</title>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adiponectin</title>
          <population>FAS Population. Missing values were imputed by LOCF. Here, overall number of participants analyzed (N) signifies those participants who were evaluable for this outcome measure.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.32"/>
                    <measurement group_id="O2" value="0.4" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A 2-sided test with a significance level of 0.05 was used for the comparison.</non_inferiority_desc>
            <p_value>0.0510</p_value>
            <method>ANCOVA</method>
            <method_desc>Randomized treatment group, baseline statin intensity, &amp; diabetes status are included as factors, &amp; outcome at baseline is included as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Framingham Risk Score</title>
        <description>Framingham Risk Score was an estimate of a participant's 10-year risk of developing cardiovascular disease which was computed using sex-specific algorithms based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) : which was derived of participant's age, systolic blood pressure , smoking status, TC, HDL-C, treatment for hypertension, and diabetes status. Reported score is a percentage. Change from baseline calculated as mean at week 12 minus mean at baseline. Negative scores indicate less risk of developing cardiovascular disease.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FAS Population. Missing values were imputed by LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcabene 600 mg</title>
            <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Framingham Risk Score</title>
          <description>Framingham Risk Score was an estimate of a participant's 10-year risk of developing cardiovascular disease which was computed using sex-specific algorithms based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) : which was derived of participant's age, systolic blood pressure , smoking status, TC, HDL-C, treatment for hypertension, and diabetes status. Reported score is a percentage. Change from baseline calculated as mean at week 12 minus mean at baseline. Negative scores indicate less risk of developing cardiovascular disease.</description>
          <population>FAS Population. Missing values were imputed by LOCF.</population>
          <units>Percentage (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.051" spread="4.1599"/>
                    <measurement group_id="O2" value="-0.850" spread="4.9889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to end of study (Up to 113 days)</time_frame>
      <desc>One participant received both treatments and is summarized under planned treatment (placebo) group for efficacy analysis and active treatment group (Gemcabene 600 mg) for safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Gemcabene 600 mg</title>
          <description>Participants on stable statin therapy received 600 mg of Gemcabene orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Immunology test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Joint crepitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nasal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Clinical Operations</name_or_title>
      <organization>NeuroBo Pharmaceuticals</organization>
      <phone>+1 (857) 702-9600</phone>
      <email>info@neurobopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

